A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell ...
According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
DENVER, CO / / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous ...
CD BioGlyco leverages its state-of-the-art platform and years of experience to deliver precise and consistent modifications to your antibody glycans. Researchers can now access homogeneous glycoforms ...
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical ...
A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled ...
Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, in collaboration with Osaka University and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results